Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2018 Jul 3;17(9):1893–1901. doi: 10.1158/1535-7163.MCT-17-0600

Fig. 2.

Fig. 2

In vivo efficacy of SAR405838 in heterotopic and orthotopic models of GBM108

A, B) Average flank tumor volume of surviving mice in placebo (black, n=7) vs. SAR405838 at 50 mg/kg p.o. qd until euthanasia (grey, n=8). Solid arrows at treatment start date. Mice were euthanized once tumor exceeded 1800 mm3. C) In vivo (flank) expression of p21 and PUMA is increased at 24 h after SAR405838 (50 mg/kg) in GBM108 but not GBM102. D) SAR405838 at the same dosing regimen does not demonstrate efficacy in an orthotopic model of GBM108. (Placebo : black (n=12), Treated : grey (n=11)) * P<0.05, ** P<0.01, *** P<0.001.